 |
|
АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология |
Ингибиторы IIв/IIIa рецепторов в РекомендацияхИнгибиторы IIв/IIIa рецепторов тромбоцитов наилучшим образом изучены у пациентов с ОКС, подвергавшихся чрескожной коронарной ангиопластике (E.Antman et al., 2004; J.Anderson et al., 2007). Однако они приносят пользу и получавшим консервативную терапию ОКС больным сахарным диабетом (M.Roffi et al., 2001). Абциксимаб является предпочтительным средством этого класса для начальной терапии перед коронарной ангиопластикой и в течение 12 часов после вмешательства (E.Topol et al., 2001). Эптифибатид и тирофибан, другие препараты этого класса, вводят на протяжении 18-24 часов после ангиопластики, причем первый обеспечивает лучшие исходы по данным проведенных исследований (E.Antman et al., 2004; J.Anderson et al., 2007). Введение абциксимаба, тирофибана или эптифибатида следует начинать как можно раньше во время первичной ангиопластики у больных ИМ с подъемами сегмента ST (F.Kushner et al., 2009). При реваскуляризации миокарда у больных с ОКС без подъемов сегмента ST при тромбообразовании в коронарной артерии рекомендован абциксимаб, в такой же ситуации у пациентов с ОКС с подъемами сегмента ST следует применять абциксимаб или эптифибатид (W.Wijns et al., 2010). Ингибиторы IIв/IIIa рецепторов увеличивают риск тяжелых кровотечений, что может приводить к повышению летальности (S.Manoukian et al., 2007). Способы снижения частоты больших кровотечений: 1) индивидуальный подбор дозы, особенно для пожилых и пациентов с нарушением функции почек (E.Antman et al., 2004; J.Anderson et al., 2007). 2) прекращение введения гепаринов после реваскуляризации (E.Karvouni et al., 2003); 3) введение ингибиторов IIв/IIIa рецепторов тромбоцитов непосредственно в лаборатории для катетеризации (и предпочтительно интракоронарно) после оценки состояния пораженных артерий (J.Wohrle et al., 2003).
Литература
Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 122: 2619–2633. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation 2007; 116: 803–877. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2004; 110: e82–e293. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329–1339. Bavry AA, Lincoff AM. Is clopidogrel cardiovascular medicine’s double-edged sword? Circulation 2006; 113: 1638–1640. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284: 1549–1558. Bhatt DL. Intensifying platelet inhibition – navigating between Scylla and Charybdis. N Engl J Med 2007; 357: 2078–2081. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002; 359: 189–198. Chen ZM, Jiang LX, Chen YP, et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–1621. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201–206. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2006; 293: 1759–1765. Ellis SG, Tendera M, de Belder MA, et al.; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205–2217. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054. Helton TJ, Bavry AA, Kumbhani DJ, et al. Incremental effect of clopidogrel on cardiovascular outcomes in patients with vascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs 2007; 7: 289–297. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations lessons from the CAPRIE and CURE Studies. Arch Intern Med 2004; 164: 2106–2110. Gurbel PA, Tantry US, Kereiakes DJ. Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthcare Patient Saf 2010; 2: 233–240. Karvouni E, Katritsis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary intervention. J Am Coll Cardiol 2003; 41: 26–32. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomized trials. Lancet 2006; 367: 579–588. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy 2010; 30: 787–796. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205–2241. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 2007; 49: 1362–1368. Mehta SR, Yusuf S, Peters RJG, et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–533. Peters RJ, Mehta SR, Fox KA, et al.; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682–1687. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a twoedged sword? Circulation 2002; 106: 379–385. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349–360. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767–2771. Sabatine MS, Cannon CP, Gibson M, et al.; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224–1232. Stone GW, Bertrand ME, Moses JW, et al.; ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA 2007; 297: 591–602. Topol EJ, Moliterno DJ, Herrmann HC, et al.; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888–1894. Wallentin L, Becker RC, Budaj A, et al. for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045–1057. Wallentin L, James S, Storey RF, et al.; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320–1328. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 2501–2555. Wiviott SD, Antman EM, Winters KJ, et al.; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 trial. Circulation 2005; 111: 3366–3373. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107: 1840–1843. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
Дата добавления: 2015-02-06 | Просмотры: 770 | Нарушение авторских прав |